Anorexia News and Research

RSS

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.

2 Nov 2011

Majority of college students could identify risk factors linked with eating disorders

They're the prime demographic for developing eating disorders, yet new research out of the University of Cincinnati suggests that it could be difficult for college students to notice the warning signs. On Oct. 31, Ashlee Hoffman, a UC doctoral student in health promotion and education, will present her research, titled, "University Students' Knowledge of An Ability to Identify Disordered Eating, Warning Signs and Risk Factors," at the American Public Health Association's 139th annual meeting and exposition in Washington, DC.

1 Nov 2011

Deficits in endocannabinoid function may contribute to eating disorders

A new report in Biological Psychiatry suggests that deficits in endocannabinoid function may contribute to anorexia nervosa and bulimia.

1 Nov 2011

Janssen announces FDA label update approval for PREZISTA HIV tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA (darunavir) tablets to include 192-week data from the ARTEMIS study.

22 Oct 2011

Positive top line results from Shire's LDX phase III study on ADHD

Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.

22 Oct 2011

State roundup: Wis. insurance savings; N.Y. major hospital merger possible; psychiatric hospitals' hard times

Minnesota Gov. Mark Dayton claimed the first major success of his drive to improve government efficiency Thursday, saying a competitive-bidding process for state health insurance programs will save $242 million in the next two years. …. Republicans, who control the state House and Senate, launched an extension of their own government-efficiency plans - labeled "Reform 2.0" - in August.

22 Oct 2011

Study links leptin levels with symptoms of depression, anxiety

A new study has for the first time in humans linked levels of leptin, a hormone produced by fat cells, with symptoms of depression and anxiety independent of weight.

21 Oct 2011

Blue Shield of Calif. adds additional $283 million to policyholder 'giveback'

Blue Shield of California says it will give customers in the state a $283-million credit on their insurance premiums, saying it is fulfilling a promise to return money to policyholders when its net income exceeds 2 percent of revenue.

15 Oct 2011

First Edition: October 14, 2011

In today's headlines, more status report on the super committee's deficit-reduction deliberations.

14 Oct 2011

HHS: Pica eating disorder hospitalizations on the rise in the U.S.

An unusual eating disorder that many people have never even heard of is attracting attention because of a recent government study that indicated the disorder is on the rise in the United States.

13 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Celgene International Sàrl was notified today that the E.U. Committee for Medicinal Products for Human Use (CHMP), on behalf of the European Medicines Agency (EMA) has concluded an Article 20 review of REVLIMID and issued a positive opinion for the use of REVLIMID in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

23 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

AHRQ finds decline in hospitalizations for pica eating disorder between 2007-2009

Eating disorders as the primary reason for entering the hospital declined by 23 percent from 2007 and 2009, after a steep and steady increase from 1999 to 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

12 Sep 2011

Roundup: Calif. ruling may extend mental health coverage; Conn. dropping early intervention program; Alaska clinic focuses on Medicare patients

A Northern California woman's treatment for anorexia at a residential facility was medically necessary and must be covered by her healthcare plan, a federal appeals court has ruled in a case that could lead to more extensive benefits for those being treated for mental illnesses.

30 Aug 2011

First Edition: August 29, 2011

Kaiser Health News staff writer Christopher Weaver, working in collaboration with The Washington Post, writes: "The federal health law calls for a huge expansion of the Medicaid program in 2014 - a potential bonanza for insurers if the law survives court challenges and opposition by Republican contenders for the White House. The expansion will add 16 million enrollees, mostly in private plans, bringing the total nationwide to about 65 million and raising the stakes for controlling costs. As budgetary pressure rises, states are increasingly passing it on to private plans".

29 Aug 2011

Leucine may help people burn fat during periods of food restriction

Research on Mt. Everest climbers is adding to the evidence that an amino acid called leucine - found in foods, dietary supplements, energy bars and other products - may help people burn fat during periods of food restriction, such as climbing at high altitude, while keeping their muscle tissue.

29 Aug 2011

Obesity a brain condition, not just a lifestyle disorder, research confirms

New Australian research has confirmed that obese individuals often perform poorly in reasoning and planning tasks and, likewise, those with poor cognitive function are more vulnerable to excessive weight gain.

23 Aug 2011

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics, has enrolled the first patient in the company's pivotal Phase III clinical program of anamorelin HCl for the treatment of anorexia/cachexia in patients with advanced non-small cell lung cancer.

23 Aug 2011

Integrated treatment approach could save lives of women with addiction

Timberline Knolls Residential Treatment Center reports people suffering from addiction rarely, if ever, have just substance abuse or addiction issues. Most addicts have trauma histories, many have mood and/or anxiety disorders, and up to 50 percent of women with substance abuse disorder have co-occurring eating disorders.

9 Aug 2011